Clinical trials: VTE Prophylaxis
Cancer, Deep-vein Thrombosis of the Lower and Upper Extremities
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
The primary objective of this study is to evaluate the practice patterns of rivaroxaban usage invenous-thromboembolism (VTE) and non-valvular atrial fibrillation (NVAF) in cancer patients.
- Conditions
- Cancer, Deep-vein Thrombosis of the Lower and Upper Extremities, Pulmonary Embolism, Non-valvular Atrial Fibrillation
- Trial name
- NCT02502396
- Testing
- Retrospective Chart Review
- Where
- United States
- Volunteers
- 265 people
- Sponsor
- M.D. Anderson Cancer Center
Venous Thromboembolism
Evaluation of Venous Thromboembolism (VTE) Prophylaxis in Medically Ill Patients
VTE prophylaxis is not as routinely employed in medically ill patients as compared to surgical patients. This retrospective chart review project will evaluate the effectiveness of VTE prophylaxis in medically ill patients at the…
- Trial name
- NCT00810784
- Testing
- Education
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- University of Utah
Venous Thromboembolism, Pulmonary Embolism
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can occasionally be life-threatening.
- Trial name
- PHACS (NCT00876915)
- Testing
- dalteparin injection
- Where
- 7 sites in United States, Canada
- Volunteers
- 218 people
- Sponsor
- University of Rochester
Venous Thromboembolism
VTE Prevention Following Total Hip and Knee Arthroplasty
Consented patients undergoing elective total hip and total knee arthroplasty will be randomized to receive either aspirin alone or aspirin and rivaroxaban for prevention of venous thromboembolism.
- Trial name
- EPCATIII (NCT04075240)
- Testing
- Rivaroxaban 10 MG and acetylsalicylic acid 81 mg, acetylsalicylic acid 81 mg
- Where
- Canada
- Volunteers
- 5,429 people
- Sponsor
- Sudeep Shivakumar
Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE)
This is a local, prospective, multicenter, non-interventional, observational study. Primary objective is to describe how in "real life" thromboprophylaxis is carried out after the discharge from a hospital in the patients who…
- Trial name
- SOPRANO (NCT01444586)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Russia
- Volunteers
- 2,293 people
- Sponsor
- Bayer
Venous Thromboembolism
Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients
This is a pilot study to evaluate safety of fondaparinux and enoxaparin in terms of bleeding and development of thrombocytopenia in the medical ICU population.
- Trial name
- NCT00493896
- Testing
- Fondaparinux, Enoxaparin
- Volunteers
- 27 people
- Sponsor
- Eastern Virginia Medical School
Cancer, VTE (Venous Thromboembolism)
DOAC - Dosing Options in AntiCoagulation Prophylaxis
Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death.
- Trial name
- DOAC (NCT07005024)
- Testing
- Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
- Where
- United States
- Volunteers
- 996 people
- Sponsor
- University of Vermont
Venous Thromboembolism
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
The primary efficacy objective is to evaluate whether dabigatran etexilate is superior to placebo in the long-term prevention of recurrent symptomatic venous thrombo-embolism (VTE) in patients with symptomatic deep-vein…
- Trial name
- RE-SONATE (NCT00558259)
- Testing
- dabigatran etexilate 150 mg twice daily (BID)
- Where
- 147 sites in United States, Australia and 19 more
- Volunteers
- 1,353 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Embolism, Deep Vein Thrombosis
Angel® Catheter Early Feasibility Clinical Study
The primary objective of this clinical trial is to obtain initial insights into the safety of the Angel® Catheter in critically ill subjects with high risk of venous thromboembolism (VTE) disease AND who are not receiving…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Trial name
- NCT01847196
- Testing
- Angel® Catheter
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- BiO2 Medical
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
The primary objective was to compare the efficacy of Semuloparin sodium (AVE5026) with Enoxaparin for the prevention of Venous Thromboembolic Events [VTE] in patients undergoing elective knee replacement surgery.
- Trial name
- SAVE-KNEE (NCT00718224)
- Testing
- Semuloparin sodium, Enoxaparin
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 1,150 people
- Sponsor
- Sanofi